



Conatus Pharmaceuticals  
Investor Relations Department  
16745 W. Bernardo Drive  
Ste 200  
San Diego, CA 92127  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: CNAT

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 5.96                       |
| Trade Time:   | 4:00 PM ET<br>Jul 26, 2017 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 1.45 - 9.40                |
| Volume        | 2                          |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

*Jul 26, 2017*

[Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results](#)

*Jul 6, 2017*

[Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of \\$7 Million Payment](#)

*Jun 26, 2017*

[FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC](#)

*Jun 16, 2017*

[Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference](#)

*May 16, 2017*

[Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](#)

### Upcoming Events [\[ View all \]](#)

*Aug 2, 2017 4:30 PM ET*

[Conatus Pharmaceuticals Second Quarter 2017 Financial Results](#)

### Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 16, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 5, 2016*

[Quarterly Report \(10-Q\)](#)